Likewise, pre-clinical investigations revealed that targeting of the IL6 signaling might be beneficial for other cancers as well, where bad prognosis is associated with high IL6 level such as renal cell carcinoma (131, 132), non-small cell lung cancer (133), and breast cancer (134). This evidence concerns the gene IL6 and hereditary clear cell renal cell carcinoma.